These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 22918780)

  • 41. 177 Lu-DOTATATE PRRT Safety and Organ-at-Risk Dosimetry in Patients With Gastroenteropancreatic Neuroendocrine Tumors : Data From the Prospective Phase 2 LUMEN Study.
    Mileva M; Van Bogaert C; Marin G; Danieli R; Artigas C; Levillain H; Ameye L; Taraji-Schiltz L; Stathopoulos K; Wimana Z; Hendlisz A; Flamen P; Karfis I
    Clin Nucl Med; 2024 Sep; 49(9):847-853. PubMed ID: 38914016
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours--impact of peptide mass.
    Velikyan I; Sundin A; Eriksson B; Lundqvist H; Sörensen J; Bergström M; Långström B
    Nucl Med Biol; 2010 Apr; 37(3):265-75. PubMed ID: 20346866
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors.
    Frilling A; Weber F; Saner F; Bockisch A; Hofmann M; Mueller-Brand J; Broelsch CE
    Surgery; 2006 Dec; 140(6):968-76; discussion 976-7. PubMed ID: 17188146
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
    Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
    J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC.
    Wehrmann C; Senftleben S; Zachert C; Müller D; Baum RP
    Cancer Biother Radiopharm; 2007 Jun; 22(3):406-16. PubMed ID: 17651048
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dosimetry and pharmacokinetics of [
    Schürrle SB; Eberlein U; Ansquer C; Beauregard JM; Durand-Gasselin L; Grønbæk H; Haug A; Hicks RJ; Lenzo NP; Navalkissoor S; Nicolas GP; Pais B; Volteau M; Wild D; McEwan A; Lassmann M
    Eur J Nucl Med Mol Imaging; 2024 Jul; 51(8):2428-2441. PubMed ID: 38528164
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Peptide receptor radionuclide therapy (PRRT) for GEP-NETs.
    Bergsma H; van Vliet EI; Teunissen JJ; Kam BL; de Herder WW; Peeters RP; Krenning EP; Kwekkeboom DJ
    Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):867-81. PubMed ID: 23582925
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Peptide receptor radionuclide therapy for non-radioiodine-avid differentiated thyroid carcinoma.
    Teunissen JJ; Kwekkeboom DJ; Kooij PP; Bakker WH; Krenning EP
    J Nucl Med; 2005 Jan; 46 Suppl 1():107S-14S. PubMed ID: 15653659
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?
    Kunikowska J; Królicki L; Hubalewska-Dydejczyk A; Mikołajczak R; Sowa-Staszczak A; Pawlak D
    Eur J Nucl Med Mol Imaging; 2011 Oct; 38(10):1788-97. PubMed ID: 21553086
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0),Tyr(3)]octreotate.
    Forrer F; Krenning EP; Kooij PP; Bernard BF; Konijnenberg M; Bakker WH; Teunissen JJ; de Jong M; van Lom K; de Herder WW; Kwekkeboom DJ
    Eur J Nucl Med Mol Imaging; 2009 Jul; 36(7):1138-46. PubMed ID: 19247653
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prospective evaluation of organ-specific dose and lesional doses following therapeutic [177Lu]Lu-EDTMP administration in patients with multiple skeletal metastases and its correlation with clinical hematological toxicity.
    Kamaldeep ; Thapa P; Wanage G; Tervankar S; Kaisar S; Ranade R; Basu S; Das T; Banerjee S
    Nucl Med Commun; 2021 Oct; 42(10):1076-1084. PubMed ID: 34528928
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [(111)In]DOTATOC as a dosimetric substitute for kidney dosimetry during [(90)Y]DOTATOC therapy: results and evaluation of a combined gamma camera/probe approach.
    Stahl A; Schachoff S; Beer A; Winter A; Wester HJ; Scheidhauer K; Schwaiger M; Wolf I
    Eur J Nucl Med Mol Imaging; 2006 Nov; 33(11):1328-36. PubMed ID: 16645839
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Biokinetics and dosimetry in patients administered with (111)In-DOTA-Tyr(3)-octreotide: implications for internal radiotherapy with (90)Y-DOTATOC.
    Cremonesi M; Ferrari M; Zoboli S; Chinol M; Stabin MG; Orsi F; Maecke HR; Jermann E; Robertson C; Fiorenza M; Tosi G; Paganelli G
    Eur J Nucl Med; 1999 Aug; 26(8):877-86. PubMed ID: 10436201
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Peptide receptor radionuclide therapy of neuroendocrine tumors].
    Arveschoug AK; Hjorthaug K; Rehling M; Højgaard L; Mortensen J; Oturai PS
    Ugeskr Laeger; 2009 Mar; 171(13):1073. PubMed ID: 19321068
    [No Abstract]   [Full Text] [Related]  

  • 55. Peptide receptor radionuclide therapy with (90)Y-DOTATATE/(90)Y-DOTATOC in patients with progressive metastatic neuroendocrine tumours: assessment of response, survival and toxicity.
    Vinjamuri S; Gilbert TM; Banks M; McKane G; Maltby P; Poston G; Weissman H; Palmer DH; Vora J; Pritchard DM; Cuthbertson DJ
    Br J Cancer; 2013 Apr; 108(7):1440-8. PubMed ID: 23492685
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy.
    Koukouraki S; Strauss LG; Georgoulias V; Schuhmacher J; Haberkorn U; Karkavitsas N; Dimitrakopoulou-Strauss A
    Eur J Nucl Med Mol Imaging; 2006 Apr; 33(4):460-6. PubMed ID: 16437218
    [TBL] [Abstract][Full Text] [Related]  

  • 57. DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy.
    Otte A; Jermann E; Behe M; Goetze M; Bucher HC; Roser HW; Heppeler A; Mueller-Brand J; Maecke HR
    Eur J Nucl Med; 1997 Jul; 24(7):792-5. PubMed ID: 9211767
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The cycle effect quantified: reduced tumour uptake in subsequent cycles of [
    Siebinga H; Hendrikx JJMA; de Vries-Huizing DMV; Huitema ADR; de Wit-van der Veen BJ
    Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):820-827. PubMed ID: 37843598
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of the pharmacokinetics of 68Ga-DOTATOC and [18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy.
    Koukouraki S; Strauss LG; Georgoulias V; Eisenhut M; Haberkorn U; Dimitrakopoulou-Strauss A
    Eur J Nucl Med Mol Imaging; 2006 Oct; 33(10):1115-22. PubMed ID: 16763820
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Lutetium DOTATATE whole body scans: A novel approach for evaluation of neuroendocrine tumors.
    Singh N; Krishna B; Vyas M; Venkatesh M; Banerjee S; Das T; Nair KV; Sudipta
    Indian J Nucl Med; 2011 Jul; 26(3):135-8. PubMed ID: 23326064
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.